Bank Of America Corp Atossa Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 73,666 shares of ATOS stock, worth $75,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,666

Previous 105,672 30.29%

Holding current value

$75,875

Previous $125,000 11.2%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.09 - $1.52 $34,886 - $48,649	-32,006 Reduced 30.29%	73,666 $111,000
Q2 2024 Aug 14, 2024	BUY	$1.03 - $2.1 $26,513 - $54,056	25,741 Added 32.2%	105,672 $125,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.89 $62,252 - $147,070	77,815 Added 3677.46%	79,931 $143,000
Q4 2023 Feb 14, 2024	BUY	$0.63 - $0.98 $199 - $309	316 Added 17.56%	2,116 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.28 $1,518 - $3,238	-2,530 Reduced 58.43%	1,800 $2,000
Q1 2023 May 12, 2023	SELL	$0.59 - $0.91 $21,077 - $32,509	-35,725 Reduced 89.19%	4,330 $3,000
Q4 2022 Feb 10, 2023	BUY	$0.5 - $1.01 $20,027 - $40,454	40,054 Added 4005400.0%	40,055 $21,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $39 - $54	-48 Reduced 97.96%	1 $0
Q2 2022 Aug 12, 2022	SELL	$0.85 - $1.28 $40,635 - $61,192	-47,807 Reduced 99.9%	49 $0
Q1 2022 May 16, 2022	SELL	$1.11 - $1.74 $88,785 - $139,177	-79,987 Reduced 62.57%	47,856 $60,000
Q4 2021 Feb 08, 2022	BUY	$1.6 - $3.27 $57,822 - $118,174	36,139 Added 39.41%	127,843 $205,000
Q3 2021 Nov 15, 2021	BUY	$2.89 - $6.4 $37,226 - $82,438	12,881 Added 16.34%	91,704 $298,000
Q2 2021 Sep 13, 2021	BUY	$1.52 - $8.62 $119,810 - $679,454	78,823 New	78,823 $498,000

Others Institutions Holding ATOS

# of Institutions

Shares Held

26.5M

Call Options Held

466K

Put Options Held

91.8K

View Full List

About ATOSSA THERAPEUTICS, INC.

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

More about ATOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Atossa Therapeutics, Inc. Transaction History